Newly Published Visiongain Report: Novel Coronavirus (COVID-19) Drugs in Development Market Forecast

Special Free Report - Please contact us for more information
CROYDON, U.K. - April 9, 2020 - PRLog -- Visiongain has launched a new pharma report Novel Coronavirus (COVID-19) Drugs in Development Market Forecast 2020-2030: Revenue Prospects by Type (Remdesivir, Chloroquine and Hydroxychloroquine, Ritonavir/Lopinavir, Ritonavir/Lopinavir + Interferon Beta, Others), Age Group (<10 Years, 10-19 Years, 20-29 Years, 30-80 Years, >80 Years) and Geography.

Coronavirus disease 2019 (COVID-19) is a respiratory disease which can spread from one person to another. The novel coronavirus was first identified during an investigation into an outbreak in Wuhan, China. The COVID-19- originally originated from an animal source, but now is spreading from person to person. The virus is thought to spread through respiratory droplets formed when an infected person coughs or sneezes primarily amongst people who are in close contact with each other (within about 6 feet). It may also be possible for a person to get COVID-19 by touching an object/surface with the virus on it, & then touching their own mouth, nose, or possibly eyes, but this is not thought to be the primary way the virus spreads.

Some of the major player operating in this industry are National Institute of Allergy and Infectious Diseases, King Abdullah International Medical Research Center, CanSino Biologics Inc, Philipps University Marburg Medical Center, Naval Medical Research Center, SAB Biotherapeutics Inc, Novavax, Gilead, Inovio, Entos Pharmaceuticals, Inc among other prominent players. Majority of the players are working towards the development of COVID-19 vaccine in order to take a leap over its counterparts. For instance, on 22nd March 2020, California based biotech firm Gilead Sciences announced that it has paused the access to its COVID-19 contender remdesivir amid overwhelming demand. The company further states that it would only be made available to pregnant women and children under 18 with severe COVID-19. Furthermore, New York based biotech firm Regeneron Pharmaceuticals is testing a cocktail of antibodies to see if they can temporarily boost immune systems to fight the virus.

Inovio has already started testing its vaccine on animals & anticipates to start human trials in April 2020. The company has finalized the designs for clinical trials & has developed large-scale manufacturing plans. Additionally, the company is planning to launch clinical trials in the United States in approximately 30 healthy volunteers.

Obtain the full report for free by clicking the link:

Sara Peerun
+44 (0) 20 7549 9987
Email:*** Email Verified
Location:Croydon - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Visiongain News
Most Viewed
Daily News

Like PRLog?
Click to Share